1[1]Cap J,Babusikova O,Kaiserova E,et al.Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission. Neoplasma,1998,45(4):231
2[2]Uckun FM, Stork L, Seibel N,et al.Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.Clin Cancer Res,2000,6(8):3123
3[3]Sievers EL, Radich JP. Detection of minimal residual disease in acute leukemia.Curr Opin Hematol,2000,7(4):212
4[4]Szczepanski T, Langerak AW, Willemse MJ, et al.T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia refelct 'end-stage' recombinations: implications for minimal residual disease monitoring.Leukemia,2000,14(7):1208
5[5]Taube T, Seeger K, Beyermann B,et al.Multiplex PCR for simultaneous detection of the most frequent T cell receptor-delta gene rearrangements in childhood ALL.Leukemia,1997,11(11):1978
6[6]Mayer SP, Giamelli J, Sandoval C, et al.Quantitation of leukemia clone-specific antigen gene rearrangements by a single-step PCR and fluorescence-based detection method.Leukemia,1999,13(11):1843
7[7]Trka J, Zuna J, Haskovec C,et al. Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia.Cas Lek Cesk,1999,138(1):12
8[8]Cayuela JM, Baruchel A, Orange C, et al.TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.Blood,1996,88(1):302
9[9]Sievers EL, Loken MR.Detection of minimal residual disease in acute myelogenous leukemia.J Pediatr Hematol Oncol,1995,17(2):123
10[10]Bolufer P, Barragan E, Verdeguer A,et al.Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.Haematologica,2002,87(1):23
3Szcepanaki T, Langerak AW, Willemse M J, et al. T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia refelct end-stage recombinations: implications for minimal residual disease monitoring. Leukemia, 2000; 14(7) : 1208.
4Compana D, Neale GAM, Coustan-Smith E, et al. Detection of minimal residual disease in acute lymphoblastic leukemia: the St Jude experienc. Leukemia, 2001; 15(2): 278.
5Bolufer P, Barragan E, Verdeguer A, et al. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes. Haematologica, 2002; 87(1) :23.
6Li AH, Rosenquist R, Forestier E, et al. Detailed clonality analysis of relapsing precursor B acute lymphoblastic leukemia: implication for minimal residual disease. Leuk Res, 2001; 25(12) : 1033.
7Coustan-Smith E, Sancho J, Hancock ML, at al. clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 2000; 96(8): 2691.
8Nyvold C, Madsen H O, Ryder L P, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood, 2002; 99(4): 1253.
9Dworzak M N, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood, 2002; 99 (6) : 1952.
10Jianbiao Z, Meredith A G, Aihong L, et al. Quantitative analysis of minimal residual discase predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consoratium Protocol 95-01. Blood, 2007; 110(5) : 1607.
